2023 年 6 月推出了更新后的国际妇产科联合会 (FIGO) 子宫内膜癌分期系统。新系统与传统的子宫内膜癌和其他妇科癌症分期系统有很大不同，传统的子宫内膜癌和其他妇科癌症分期系统与肿瘤类型、肿瘤分级等参数无关。 、淋巴管间隙侵入和分子改变。更新后的系统包含所有这些“非解剖”参数，旨在使分期更加个性化并与患者预后和管理相关，并与欧洲妇科肿瘤学会/欧洲放射治疗和肿瘤学会/欧洲病理学会 (ESGO/ESTRO/ESP) 风险分层。在此，我们对新的分期系统进行了严格的审查，并讨论了其优点和缺点。作者建议，新的FIGO分期系统应首先在多机构和全球层面进行评估，并吸收所有相关学会（妇科、病理学、妇科肿瘤学、内科肿瘤学、放射肿瘤学）的意见，以了解其影响、范围和拟议变更的支持证据。这样的过程对于产生病理学家和治疗临床医生可以采用的强大系统至关重要。© IGCS 和 ESGO 2023。禁止商业重复使用。请参阅权利和权限。由英国医学杂志出版。

An updated International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma was introduced in June 2023. The new system represents a significant departure from traditional endometrial and other gynecological carcinoma staging systems which are agnostic of parameters such as tumor type, tumor grade, lymphovascular space invasion, and molecular alterations. The updated system, which incorporates all of these 'non-anatomical' parameters, is an attempt to make staging more personalized and relevant to patient prognostication and management, and to align with the European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology (ESGO/ESTRO/ESP) risk stratification. Herein, we present a critical review of the new staging system and discuss its advantages and disadvantages. The authors propose that the new FIGO staging system should be first appraised at a multi-institutional and global level with the input of all relevant societies (gynecology, pathology, gynecologic oncology, medical oncology, radiation oncology) to understand the impact, scope, and supporting evidence of the proposed changes. Such a process is fundamental to produce a robust system that pathologists and treating clinicians can adopt.© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.